Data Year:

For its 2024 fiscal year, Cytek Biosciences, Inc., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Business Services industry
Patrik Jeanmonod
Former Chief Financial Officer
Total Compensation $758,170 View details Pay Rank By Title In Business Services industry #451 View more
Wenbin Jiang Ph.D.
Chief Executive Officer and President
Total Compensation $6,084,671 View details Pay Rank By Title In Business Services industry #276 View more
Ming Yan Ph.D.
Chief Technology Officer
Total Compensation $1,856,550 View details Pay Rank By Title In Business Services industry #71 View more
Valerie Barnett
Chief Legal Officer and Corporate Secretary
Total Compensation $2,410,488 View details Pay Rank By Title In Business Services industry #50 View more
Philippe Busque Ph.D.
Senior Vice President, Global Sales and Services
Total Compensation $1,004,760 View details Pay Rank By Title In Business Services industry #4 View more
Chris Williams
Former Chief Operating Officer
Total Compensation $2,338,447 View details Pay Rank By Title In Business Services industry #93 View more
William McCombe
Chief Financial Officer
Total Compensation $1,689,262 View details Pay Rank By Title In Business Services industry #339 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Cytek Biosciences, Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Cytek Biosciences, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Cytek Biosciences, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Patrik Jeanmonod
Former Chief Financial Officer
Total Cash $344,831 Equity $399,989 Other $13,350 $758,170
Wenbin Jiang Ph.D.
Chief Executive Officer and President
Total Cash $1,071,760 Equity $4,999,990 Other $12,921 $6,084,671
Ming Yan Ph.D.
Chief Technology Officer
Total Cash $592,605 Equity $1,249,991 Other $13,954 $1,856,550
Valerie Barnett
Chief Legal Officer and Corporate Secretary
Total Cash $646,699 Equity $1,749,995 Other $13,794 $2,410,488
Philippe Busque Ph.D.
Senior Vice President, Global Sales and Services
Total Cash $504,768 Equity $499,992 Other $0 $1,004,760
Chris Williams
Former Chief Operating Officer
Total Cash $323,878 Equity $1,999,994 Other $14,575 $2,338,447
William McCombe
Chief Financial Officer
Total Cash $439,268 Equity $1,249,994 Other $0 $1,689,262
For its 2024 fiscal year, Cytek Biosciences, Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Deborah Neff Total Cash $244,992
Don Hardison Total Cash $242,492
Gisele Dion Total Cash $33,427
Jack Ball Total Cash $284,992
Michael Holder Total Cash $339,997
Vera Imper, Ph.D. Total Cash $244,278
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.